Gene Therapy for Respiratory Diseases: Progress and a Changing Context

Griesenbach U , Pytel KM , Alton EWFW . Cystic fibrosis gene therapy in the UK and elsewhere. Hum Gene Ther, 2015; 26:266–275.

Riordan JR , Rommens JM , Kerem BS , et al. Identification of the cystic fibrosis gene—cloning and characterization of complementary DNA. Science, 1989; 245:1066–1072.

Dorfman R , Crowdy E , Bear C , et al. Cystic Fibrosis Mutation Database. www.genet.sickkids.on.ca/cftr (last accessed May 28, 2020 ).

Wang Y , Wrennall JA , Cai Z , et al. Understanding how cystic fibrosis mutations disrupt CFTR function: from single molecules to animal models. Int J Biochem Cell Biol, 2014; 52:47–57.

Cuyx S , De Boeck K . Treating the underlying cystic fibrosis transmembrane conductance regulator defect in patients with cystic fibrosis. Semin Respir Crit Care Med, 2019; 40:762–774.

Han ST , Rab A , Pellicore MJ , et al. Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators. JCI Insight, 2018; 3:e121159.

Shteinberg M , Taylor-Cousar JL . Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease. Eur Respir Rev, 2020; 29:190112.

Vertex and treating CF costs can unsettle, but Vertex remains close to community. cysticfibrosisnewstoday.com/2018/09/24/vertex-and-treating-cf-costs-can-unsettle-but-vertex-remains-close-to-community-interview-series (last accessed May 28, 2020).

Cystic Fibrosis Foundation launches $500 million path to a cure. www.cff.org/About-Us/Media-Center/Press-Releases/Cystic-Fibrosis-Foundation-Launches-$500-Million-Path-to-a-Cure (last accessed May 28, 2020 ).

Alton EWFW , Armstrong DK , Ashby D , et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med, 2015; 3:684–691.

Sinn PL , Arias AC , Brogden KA , et al. Lentivirus vector can be readministered to nasal epithelia without blocking immune responses. J Virol, 2008; 82:10684–10692.

Griesenbach U , Inoue M , Meng C , et al. Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy. Am J Respir Crit Care Med, 2012; 186:846–856.

Malin R . New partnership develops gene therapy for cystic fibrosis. www.boehringer-ingelheim.com/press-release/new-partnership-develop-gene-therapy-cystic-fibrosis (last accessed May 28, 2020 ).

Spirovant Sciences. SPIRO-2102 lentiviral vector-based cystic fibrosis gene therapy. www.life-sciences-europe.com/product/spiro-2102-lentiviral-vector-spirovant-sciences-sumitomo-group-2001-31603.html (last accessed May 28, 2020 ).

Auricchio A , O'Connor E , Weiner D , et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest, 2002; 110:499–504.

Limberis MP , Wilson JM . Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci U S A, 2006; 103:12993–12998.

Sinn PL , Burnight ER , McCray PB . Progress and prospects: prospects of repeated pulmonary administration of viral vectors. Gene Ther, 2009; 16:1059–1065.

Schlimgen R , Howard J , Wooley D , et al. Risks associated with lentiviral vector exposures and prevention strategies. J Occup Environ Med, 2016; 58:1159–1166.

Corrigan-Curay J , Cohen-Haguenauer O , O'Reilly M , et al. Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther, 2012; 20:1084–1094.

Wall DA , Krueger J . Chimeric antigen receptor T cell therapy comes to clinical practice. Curr Oncol, 2020; 27:S115–S123.

Alton EWFW , Beekman JM , Boyd AC , et al. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax, 2016; 72:137–147.

Mitomo K , Griesenbach U , Inoue M , et al. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with sendai virus envelopes. Mol Ther, 2010; 18:1173–1182.

Sinn PL , Anthony RM , McCray PB . Genetic therapies for cystic fibrosis lung disease. Hum Mol Genet, 2011; 20:R79–R86.

Wilson RC , Gilbert LA . The promise and challenge of in vivo delivery for genome therapeutics. ACS Chem Biol, 2018; 13:376–382.

Hodges CA , Conlon RA . Delivering on the promise of gene editing for cystic fibrosis. Genes Dis, 2019; 6:97–108.

Mention K , Santos L , Harrison PT . Gene and base editing as a therapeutic option for cystic fibrosis-learning from other diseases. Genes Basel, 2019; 10:387.

Goss CH , Mayer-Hamblett N , Kronmal RA , et al. The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases. Adv Drug Deliv Rev, 2002; 54:1505–1528.

De Boeck K , Bulteel V , Tiddens H , et al. Guideline on the design and conduct of cystic fibrosis clinical trials: the European Cystic Fibrosis Society—Clinical Trials Network (ECFS-CTN). J Cyst Fibros, 2011; 10 Suppl 2:S67–S74.

De Boeck K , Lee T , Amaral M , et al. Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view. J Cyst Fibros, 2020;S1569-1993(20)30162-4.

Habib AR , Kajbafzadeh M , Desai S , et al. A systematic review of the clinical efficacy and safety of CFTR modulators in cystic fibrosis. Sci Rep, 2019; 9:7234.

Burney TJ , Davies JC . Gene therapy for the treatment of cystic fibrosis. Appl Clin Genet, 2012; 5:29–36.

Bremer S , Hoof T , Wilke M , et al. Quantitative expression patterns of multidrug-resistance P- glycoprotein (MDR1) and differentially spliced cystic-fibrosis transmembrane-conductance regulator mRNA transcripts in human epithelia. Eur J Biochem, 1992; 206:137–149.

Wagner JA , Nepomuceno IB , Messner AH , et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther, 2002; 13:1349–1359.

Mendes F , Doucet L , Hinzpeter A , et al. Immunohistochemistry of CFTR in native tissues and primary epithelial cell cultures. J Cyst Fibros, 2004; 3 Suppl 2:37–41.

Davidson H , Wilson A , Gray RD , et al. An immunocytochemical assay to detect human CFTR expression following gene transfer. Mol Cell Probes, 2009; 23:272–280.

Knowles MR , Paradiso AM , Boucher RC . In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther, 1995; 6:445–455.

Sermet-Gaudelus I , Girodon E , Roussel D , et al. Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis. Thorax, 2010; 65:539–544.

Muhlebach MS , Clancy JP , Heltshe SL , et al. Biomarkers for cystic fibrosis drug development. J Cyst Fibros, 2016; 15:714–723.

Kyrilli S , Henry T , Wilschanski M , et al. Insights into the variability of nasal potential difference, a biomarker of CFTR activity. J Cyst Fibros, 2020; 19:620–626.

Naehrlich L , Ballmann M , Davies J , et al. Nasal potential difference measurements in diagnosis of cystic fibrosis: an international survey. J Cyst Fibros, 2014; 13:24–28.

Davies JC , Davies M , McShane D , et al. Potential difference measurements in the lower airway of children with and without cystic fibrosis. Am J Respir Crit Care Med, 2005; 171:1015–1019.

Stanojevic S , Wade A , Stocks J . Reference values for lung function: past, present and future. Eur Respir J, 2010; 36:12–19.

Davies JC , Cunningham S , Alton EWFW , et al. Lung clearance index in CF: a sensitive marker of lung disease severity. Thorax, 2008; 63:96–97.

Saunders C , Bayfield K , Irving S , et al. Developments in multiple breath washout testing in children with cystic fibrosis. Curr Med Res Opin, 2017; 33:613–620.

Saunders C , Jensen R , Robinson PD , et al. Integrating the multiple breath washout test into international multicentre trials. J Cyst Fibros. 2020; 19:602–607.

Stahl M , Wielputz MO , Graeber SY , et al. Comparison of lung clearance index and magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis. Am J Respir Crit Care Med, 2017; 195:349–359.

Martini K , Gygax CM , Benden C , et al. Volumetric dynamic oxygen-enhanced MRI (OE-MRI): comparison with CT Brody score and lung function in cystic fibrosis patients [published correction appears in Eur Radiol. 2018 Jun 12;:]. Eur Radiol, 2018; 28:4037–4047.

Shirley JL , De Jong YP , Terhorst C , et al. Immune responses to viral gene therapy vectors. Mol Ther, 2020; 28:709–722.

Fischer A , Hacein-Bey-Abina S . Gene therapy for severe combined immunodeficiencies and beyond. J Exp Med, 2020; 217:e20190607.

Mohanlal R , Qiu Y , Zheng M , et al. Long-term safety follow-up of subjects previously treated with non-replicating retroviral vector-based gene therapies. Mol Diagn Ther, 2016; 20:591–602.

Food and Drug Administration. Long Term Follow-up After Administration of Human Gene Therapy Products. Guidance for Industry. www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products (last accessed May 28, 2020 ).

Kolb M , Martin G , Medina M , et al. Gene therapy for pulmonary diseases. Chest, 2006; 130:879–884.

Chiuchiolo MJ , Crystal RG . Gene therapy for alpha-1 antitrypsin deficiency lung disease. Ann Am Thorac Soc, 2016; 13 Suppl 4:S352–S369.

Curiel DT , Pilewski JM , Albelda SM . Gene therapy approaches for inherited and acquired lung diseases. Am J Respir Cell Mol Biol, 1996; 14:1–18.

Lu Q , El-Hashash AHK . Cell-based therapy for idiopathic pulmonary fibrosis. Stem Cell Investig, 2019; 6:22.

Al-Jamal R , Wallace WA , Harrison DJ . Gene therapy for chronic obstructive pulmonary disease: twilight or triumph?. Expert Opin Biol Ther, 2005; 5:333–346.

Paul-Smith M , Gelinas J , Pytel K , et al. Gene therapy for alpha-1-antitrypsin deficiency using a pseudotyped lentivirus vector. Thorax, 2015; 70(Suppl 3):A72–A73.

Lund-Palau H , Meng C , Pilou A , et al. Lentivirus GM-CSF gene therapy ameliorates autoimmune pulmonary alveolar proteinosis. Thorax, 2018; 73(Suppl 4):A1–A2.

Paul-Smith MC , Pytel KM , Gelinas JF , et al. The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins. Gene Ther, 2018; 25:345–358.

Bakker JM , Bleeker WK , Parren PW . Therapeutic antibody gene transfer: an active approach to passive immunity. Mol Ther, 2004; 10:411–416.

Touchot N , Flume M . Early insights from commercialization of gene therapies in Europe. Genes Basel, 2017; 8:78.

Burki TK . Negotiations between the NHS and Vertex on access to lumacaftor and ivacaftor become protracted. Lancet Respir Med, 2019; 7:739–740.

Silverman E . Oh, Canada! Vertex battles another country over access to cystic fibrosis treatments. www.statnews.com/pharmalot/2020/03/04/vertex-canada-cystic-fibrosis (last accessed May 28, 2020 ).

Valkama AJ , Oruetxebarria I , Lipponen EM , et al. Development of large-scale downstream processing for lentiviral vectors. Mol Ther Methods Clin Dev, 2020; 17:717–730.

Kelly J . Environmental scan of cystic fibrosis research worldwide. J Cyst Fibros, 2017; 16:367–370.